FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review - MarketWatch

FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review MarketWatch - 15 hours ago A Prescription Drug User Fee Act (PDUFA) target date of April 2, 2009 has been established by the FDA for a decision regarding the approval of the Zevalin ... US FDA Grants Pralatrexate Orphan Drug Designation for the ... WELT ONLINE Cell Therapeutics says FDA grants priority review for Zevalin sBLA ... RTT News all 44 news articles

Treatment options, success rates vary for prescription opioid abusers - AAP News (subscription)

Treatment options, success rates vary for prescription opioid abusers AAP News (subscription) - 3 hours ago In just six months, Jessica S. went from using drugs with her boyfriend to a drug rehabilitation center. Her psychedelic experimentation began with ...

Alkermes Regains Full Commercialization Rights to VIVITROL(R) in US - MarketWatch

Alkermes Regains Full Commercialization Rights to VIVITROL(R) in US MarketWatch - 8 hours ago (7) In 2005, the European Monitoring Centre for Drugs and Drug Addiction estimated the prevalence of problem opioid use in Europe to be in the range of 1.3 ...

PRI's ''The World'' Tracks the Arduous Route of an AIDS Treatment ... - MarketWatch

PRI's ''The World'' Tracks the Arduous Route of an AIDS Treatment ... MarketWatch - 34 minutes ago Support for PRI's "The World" comes from Merck, the Medtronic Foundation and the Capital Group Companies; by grants from the Bill & Melinda Gates Foundation ...

Teva Grabs Billions Gambling on Copies of Brand Drugs (Update2) - Bloomberg

Teva Grabs Billions Gambling on Copies of Brand Drugs (Update2) Bloomberg - 18 minutes ago In the 1980s Teva expanded into the US through acquisitions and a 1984 law that grants six months’ exclusivity to the first generic-drug maker challenging ...